These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 32428509)

  • 1. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing in Non-small Cell Lung Cancer.
    Perrotta F; Nankivell M; Adizie JB; Maqsood U; Elshafi M; Jafri S; Lerner AD; Woolhouse I; Munavvar M; Evison M; Booton R; Baldwin DR; Janes SM; Kerr KM; Bianco A; Yarmus L; Navani N
    Chest; 2020 Sep; 158(3):1230-1239. PubMed ID: 32428509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed Death Ligand 1 Testing of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Samples Acquired For the Diagnosis and Staging of Non-Small Cell Lung Cancer.
    Smith A; Wang H; Zerbo A; Beaudoin S; Ofiara L; Fiset PO; Benedetti A; Gonzalez AV
    J Bronchology Interv Pulmonol; 2020 Jan; 27(1):50-57. PubMed ID: 31513030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Programmed Death Ligand-1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens.
    Sakata KK; Midthun DE; Mullon JJ; Kern RM; Nelson DR; Edell ES; Schiavo DN; Jett JR; Aubry MC
    Chest; 2018 Oct; 154(4):827-837. PubMed ID: 30059678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
    Yoshimura K; Inoue Y; Karayama M; Tsuchiya K; Mori K; Suzuki Y; Iwashita Y; Kahyo T; Kawase A; Tanahashi M; Ogawa H; Yokomura K; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Lung Cancer; 2019 Aug; 134():202-209. PubMed ID: 31319982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens.
    Tajarernmuang P; Ofiara L; Beaudoin S; Wang H; Benedetti A; Gonzalez AV
    Chest; 2021 Aug; 160(2):743-753. PubMed ID: 33675792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endobronchial Ultrasound Guided Transbronchial Needle Aspiration and PD-L1 Yields.
    Khoury LM; Sheehan KN; Mariencheck WI; Gershner KA; Maslonka M; Niehaus AG; Isom S; Bellinger CR
    Lung; 2024 Jun; 202(3):325-330. PubMed ID: 38637361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic yield of endobronchial ultrasound-guided transbronchial needle aspiration to assess tumor-programmed cell death ligand-1 expression in mediastinal lymph nodes metastasized from non-small cell lung cancer.
    Mineura K; Hamaji M; Yoshizawa A; Nakajima N; Kayawake H; Tanaka S; Yamada Y; Yutaka Y; Nakajima D; Ohsumi A; Menju T; Chen-Yoshikawa TF; Date H
    Surg Today; 2020 Sep; 50(9):1049-1055. PubMed ID: 32166496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suitability of endobronchial ultrasound-guided transbronchial needle aspiration samples for programmed death ligand-1 testing in non-small cell lung cancer, the Bristol experience.
    Hardy J; Bhatt N; Medford ARL
    Asia Pac J Clin Oncol; 2022 Apr; 18(2):e32-e38. PubMed ID: 33870634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical performance of endobronchial ultrasound-guided transbronchial needle aspiration for assessing programmed death ligand-1 expression in nonsmall cell lung cancer.
    Biswas A; Leon ME; Drew P; Fernandez-Bussy S; Furtado LV; Jantz MA; Mehta HJ
    Diagn Cytopathol; 2018 May; 46(5):378-383. PubMed ID: 29476608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of endobronchial ultrasound transbronchial needle aspiration as the first nodal staging procedure for the determination of programmed death ligand-1 expression in non-small cell lung cancer patients.
    Polanco D; Pinilla L; Gracia-Lavedan E; Gatius S; Zuil M; Pardina M; Gómez S; Barbé F
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):12459-12468. PubMed ID: 37450028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer.
    Sakakibara R; Inamura K; Tambo Y; Ninomiya H; Kitazono S; Yanagitani N; Horiike A; Ohyanagi F; Matsuura Y; Nakao M; Mun M; Okumura S; Inase N; Nishio M; Motoi N; Ishikawa Y
    Clin Lung Cancer; 2017 Sep; 18(5):527-534.e1. PubMed ID: 28111119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples.
    Gürün Kaya A; Çiledağ A; Erol S; Öz M; Doğan Mülazımoğlu D; Işık Ö; Özakıncı H; Çiftçi F; Şen E; Ceyhan K; Kaya A; Karnak D; Çelik G; İsmail S
    Scott Med J; 2022 Feb; 67(1):18-27. PubMed ID: 35147461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of programmed death ligand 1 expression in paired cytologic and histologic specimens of non-small cell lung cancer.
    Daverio M; Patrucco F; Gavelli F; Airoldi C; Sciortino G; Chiaramonte C; Rena O; Balbo PE; Boldorini RL
    Cancer Cytopathol; 2020 Aug; 128(8):580-588. PubMed ID: 32463583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of
    Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
    Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
    Jug R; Giovacchini CX; Liu B; Green CL; Clarke JM; Mahmood K; Pavlisko EN
    J Am Soc Cytopathol; 2020; 9(6):485-493. PubMed ID: 32336671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer.
    Tsunoda A; Morikawa K; Inoue T; Miyazawa T; Hoshikawa M; Takagi M; Mineshita M
    BMC Cancer; 2019 Jun; 19(1):546. PubMed ID: 31174496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suitability of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration versus Paired Transbronchial Biopsy Specimens for Evaluating Programmed Death Ligand-1 Expression in Stage III and IV Lung Cancer: A Comparative Retrospective Study.
    Matsuoka H; Araya T; Kita T; Terada N; Yamamura K; Nishikawa S; Tambo Y; Sone T; Kimura H; Ooi A; Kasashima S; Kawashima A; Kasahara K
    J Cancer; 2021; 12(15):4478-4487. PubMed ID: 34149911
    [No Abstract]   [Full Text] [Related]  

  • 18. Feasibility and reliability of evaluate PD-L1 expression determination using small biopsy specimens in non-small cell lung cancer.
    Chen M; Xu Y; Zhao J; Li J; Liu X; Zhong W; Wang M
    Thorac Cancer; 2021 Sep; 12(17):2339-2344. PubMed ID: 34291566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Handling and standardization of EBUS needle aspiration in NSCLC patients: The value of the cell block, a monoinstitutional experience.
    Parente P; Carbonelli C; Biancofiore G; Sukthi A; Di Micco CM; Vairo M; Fuso P; Taurchini M; Graziano P
    Thorac Cancer; 2022 Sep; 13(17):2480-2488. PubMed ID: 35868633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Hara N; Ichihara E; Harada D; Inoue K; Fujiwara K; Hosokawa S; Kishino D; Haruyuki K; Ochi N; Oda N; Hotta K; Maeda Y; Kiura K
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3749-3755. PubMed ID: 33779840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.